130 mm

255 mm

Pharmacode Reads This Way

First Bar

Last Bar

SCHEDULING STATUS

S0

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM

Fybogel® Orange Powder

Ispaghula husk 3,5 g per sachet

Read all of this leaflet carefully because it contains important information for you.
FYBOGEL ORANGE is available without a doctor's prescription, for you to treat a mild illness. Nevertheless, you still need to use FYBOGEL ORANGE carefully to get the best results from it. Keep this leaflet. You may need to read it again. Do not share FYBOGEL ORANGE with any other person. Ask your pharmacist if you need more information or advice. You must see a doctor if your symptoms worsen or do not improve after 3 days.

1. WHAT FYBOGEL ORANGE CONTAINS
The active substance is 3, 5 g of Ispaghula husk in each sachet
Other ingredients include: citric acid anhydrous, potassium bicarbonate, sodium bicarbonate, orange flavour, beta-carotene, riboflavin sodium phosphate, polysorbate 80 & silica colloidal (anhydrous). Contains sweeteners –(aspartame 0,016 g and saccharin sodium 0,012 g per sachet)

2. WHAT FYBOGEL ORANGE IS USED FOR
Fybogel is recommended for the treatment of patients requiring a high-fibre regimen, for constipation and for those requiring normalisation of faecal consistency as in irritable bowel syndrome and diverticular disease.

3. BEFORE YOU TAKE FYBOGEL ORANGE
***Do not take* FYBOGEL ORANGE:**
- If you are allergic to Ispaghula or any of the other ingredients of FYBOGEL ORANGE.
- If you are suffering from a blockage of the bowel (intestinal obstruction or faecal impaction)
- If you have rectal bleeding and you are not able to defecate following the use of a laxative
- If you have a condition called phenylketonuria, because the product is sweetened with aspartame which is a source of phenylalanine.
- If you are on a salt restricted diet
- If you have a dysfunctional digestive system, irrespective of the cause
- If you are suffering from abnormal constrictions in the gastro-intestinal tract, with diseases of the oesophagus and cardia, intestinal obstruction, faecal impaction, natural or drug induced reduction of digestive system motility and colonic atony such as senile mega colon.
- If you have faecal impaction and symptoms such as abdominal pain, nausea and vomiting.

Special care should be taken with FYBOGEL ORANGE
- If you have difficulty in swallowing
- If you have a sudden change in bowel habit that has persisted for more than 2 weeks, consult a doctor before using laxatives.
- If you are below the age of 6, laxative bulk producers should be used before using other purgatives if change of nutrition is not successful.
- If you have abdominal pain
- If you have intestinal narrowing decreased intestinal motility in the elderly or debilitated patient as rare instances of gastrointestinal obstruction have been reported, especially when these medicines are taken with insufficient liquid.

FYBOGEL ORANGE should not be taken dry and should always be taken mixed with fluid (8 fluid ounces or 240 mL of water or other liquid per sachet). When taken with inadequate fluid amounts, bulk forming medicines can cause obstruction of the throat and oesophagus with choking and intestinal obstruction. Symptoms can be chest pain, vomiting, or difficulty in swallowing or breathing.
If abdominal pain occurs or in cases of any irregularity of faeces, the use of FYBOGEL ORANGE should be discontinued, and medical advice must be sought after one week. The treatment of debilitated patients and / or elderly patients requires medical supervision. FYBOGEL ORANGE should not be used together with medicines known to inhibit peristaltic movement (e.g.opioids) Persistent constipation should be investigated. The habitual use of laxatives should be avoided. FYBOGEL ORANGE should be taken with adequate liquid to prevent faecal impactation and oesophageal obstruction. Rectal bleeding or failure to have a bowel movement after use of a laxative may indicate a serious condition. Discontinue use and consult a doctor.

Hypersensitivity
ISPAGHULA husk contains potent allergens. Exposure to these allergens is possible through oral administration, contact with the skin and, in the case of powder formulations, also by inhalation. As a consequence to this allergic potential, individuals exposed to FYBOGEL ORANGE can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxis. Cutaneous symptoms such as exanthema and/or pruritus have also been reported.

Pregnancy and breastfeeding:
Safety and efficacy in pregnancy and breastfeeding has not been established.
Ispaghula is not absorbed, nor is it thought to enter the breast milk. If you are pregnant or breastfeeding your baby while taking FYBOGEL ORANGE. please consult your doctor, pharmacist or other healthcare professional for advice.

Driving and using machines:
No precautions are necessary. No effect on ability to drive and use machines

Taking other medicine with FYBOGEL ORANGE
Always tell your healthcare professional if you are taking any other medicine.
(This includes complementary or traditional medicines).
FYBOGEL ORANGE and other bulk-forming laxatives may delay or reduce the gastrointestinal absorption of other medicines such as cardiac glycosides, Warfarin, lithium, or vitamins (such as vitamin B12) and minerals (such as calcium, iron, or zinc). For this reason, FYBOGEL ORANGE should not be taken ½ to 1 hour before or after intake of other medicines.
Diabetic patients should take ispaghula husk only under medical supervision because adjustment of anti-diabetic therapy may be necessary. Use of ISPAGHULA husk concomitantly with thyroid hormones requires medical supervision because the dose of the thyroid hormones may have to be adjusted.

4. HOW TO TAKE FYBOGEL ORANGE
Oral administration.
FYBOGEL ORANGE should not be taken by children below 6 years of age
Always take FYBOGEL ORANGE exactly as stated in this package leaflet or as your doctor, pharmacist or nurse has told you. You should check with your doctor or pharmacist or nurse if you are not sure. Unless otherwise prescribed by your doctor, the usual dose is ***Adults and children over 12 years*** One sachet stirred into a full glass of water taken in the morning and evening

Elderly: There is no indication that dosage needs to be modified for the elderly.

Children 6 to 12 years
½ - 1 level 5 ml medicine measure (depending on age and size) stirred into a full glass of water taken morning and evening.
The product should be taken during the day at least ½ to 1 hour before or after intake of other medicines and should not be taken immediately before going to sleep. FYBOGEL ORANGE should be stirred into a glass of water and taken as soon as possible, preferably after meals.
If there have been no bowel movements after 3 days of treatment a doctor should be consulted.
The effects start 12-24 hours later.
When preparing FYBOGEL ORANGE for administration, it is important to try to avoid inhaling any of the powder in order to minimize the risk of sensitization to the active ingredient.
If you take more FYBOGEL ORANGE than you should
In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison control center. The following signs may occur abdominal discomfort, flatulence and intestinal obstruction.
Treatment:
Treatment is symptomatic and supportive. An adequate fluid intake should be maintained, particularly if the granules have been taken without water. In the event of overdosage, conservative measures should be taken. The patient may notice abdominal discomfort and flatulence and attention should be paid to maintaining an adequate fluid intake, (particularly if the powder has been taken without water, contrary to the administration instructions.)

5. POSSIBLE SIDE EFFECTS
FYBOGEL ORANGE can have side effects.
More frequent:
Gastrointestinal disorders: Flatulence, abdominal distension.
Oesophageal or intestinal obstruction or faecal impaction have been reported. Not all side effects reported for this medicine are included in this leaflet. Should your general health worsen while taking this medicine, please consult your doctor, pharmacist or other health care professional for advice.

6. STORING AND DISPOSING OF FYBOGEL ORANGE
Store all medicines out of reach of children. Do not use FYBOGEL ORANGE after the expiry date which is stated on the carton.
Store at or below 25 °C in a dry place.
Do not dispose of unused medicine in drains or sewage systems.

7. PRESENTATION OF FYBOGEL ORANGE
Presented in cartons containing 10 and 30 sachets. Each sachet contains 4,377 g of FYBOGEL ORANGE

8. IDENTIFICATION OF FYBOGEL ORANGE
Buff-coloured semi-transparent granules with an orange odour

9. REGISTRATION NUMBER
M/11.5/1

10. NAME, BUSINESS ADRESS AND TELEPHONE NUMBER OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION
Reckitt Benckiser Pharmaceuticals (Pty) Ltd
8 Jet Park Road
Elandsfontein 1601
+2711 871 1611

11. DATE OF PUBLICATION OF THIS PATIENT INFORMATION LEAFLET
- Date on the registration certificate: 15 May 1981
- Date of the most recently revised professional information leaflet: 15 April 2020

Please go to the link for access to the corresponding PI:
https://cpdcentre.co.za/product-inserts/FYBOGEL-ORANGE-Powder.pdf

Namibia	90/11.5/001390 (NS0)

Part No. 3189445

Pharmacode Reads This Way

Last Bar

First Bar

SKEDULERINGSTATUS

S0

EIENDOMSNAAM, STERKTE EN FARMASEUTIESE VORM

Fybogel® Orange Poeier

Ispaghula-doppe 3,5 g per sakkie

Lees hierdie hele pamflet noukeurig deur want dit bevat belangrike inligting vir u.
FYBOGEL ORANGE is beskikbaar sonder 'n voorskrif van 'n dokter, vir jou om matige siektes te behandel.
Ongeag moet u steeds FYBOGEL ORANGE versigtig gebruik om die beste resultate daaruit te kry.
Bewaar hierdie pamflet. Dit mag nodig wees om dit weer te lees.
Moet nie FYBOGEL ORANGE met enige ander persoon deel nie.
Vra u apteker indien u meer inligting of advies benodig
Sien u dokter indien u simptome vererger of na sewe dae nie verbeter nie.

1. WAT FYBOGEL ORANGE BEVAT
Die aktiewe middel is 3,5 g Ispaghula-doppe in elke sakkie
Ander bestanddele sluit in:
Anhidriese sitroensuur, kaliumbikarbonaat, natriumbikarbonaat, lemoen geursel, betakaroteen, riboflavien natriumfosfaat, polisorbaat 80, kolloïdale silika (anhidries)
Bevat versoeters -(aspartaam 0,016 g en natrium sakkarien 0,012 g per sakkie)

2. WAARVOOR FYBOGEL ORANGE GEBRUIK WORD
Fybogel word aanbeveel vir die behandeling van pasiënte wat 'n veselryke dieet benodig, vir hardlywigheid en vir diegene wat normalisering van ontlasting as 'n prikkelbare dermsindroom en divertikulêre siekte benodig.

3. VOORDAT U FYBOGEL ORANGE GEBRUIK
Moet nie* FYBOGEL ORANGE *neem:
- Indien u allergies is vir Ispaghula of enige ander van die bestanddele van FYBOGEL ORANGE nie.
- As u lei aan verstopping van die derm (dermobstruksie of fekale impaksie)
- As u rektale bloeding het en u nie kan ontlas na die gebruik van 'n lakseermiddel nie
- Indien u 'n toestand het wat fenielketonurie genoem word, omdat die produk versoet is met aspartaam wat 'n bron van fenielalanien is.
- As u 'n soutbeperkte dieet het
- As u 'n disfunksionele spysverteringstelsel het, ongeag die oorsaak
- As u ly aan abnormale vernouings in die spysverteringskanaal, met siektes van die slukderm en kardia, dermobstruksie, fekale impaksie, natuurlike of dwelm-geïnduseerde vermindering van die spysverteringstelsel se beweeglikheid en kolonatonie, soos seniele megakolon.
- As u fekale impaksie het en simptome soos buikpyn, naarheid en braking het.

Neem spesiale sorg met FYBOGEL ORANGE
- As u sukkel om te sluk
- As u 'n skielike verandering in derm gewoontes wat langer as 2 weke duur, raadpleeg 'n dokter voordat u lakseermiddels gebruik.
- Indien u jonger as 6 is, moet bulkvormende lakseermiddels gebruik word voordat ander purgeermiddels gebruik word indien die verandering van voeding nie suksesvol is nie.
- As u buikpyn het
- As u derms vernou, die derm beweeglikheid by bejaardes of verswakte pasiënte verlaag, aangesien daar seldsame gevalle van gastro-intestinale obstruksie gerapporteer is, veral as hierdie medisyne saam met onvoldoende vloeistof geneem word.

FYBOGEL ORANGE behoort nie droog geneem te word nie en moet altyd met vloeistof gemeng word vir inname (8 vloeistof onse of 240 ml water of ander vloeistof per sakkie).
Wanneer dit met 'n onvoldoende hoeveelheid vloeistof geneem word, kan bulkvormende medisyne obstruksie van die keel en slukderm veroorsaak deur verstikking en dermobstruksie.
Simptome kan borspyn, braking of probleme met sluk of asemhaling
Indien buikpyn voorkom of in gevalle van enige onreëlmatigheid van ontlasting, moet die gebruik van FYBOGEL ORANGE gestaak word, en mediese advies moet na een week versoek word.
Die behandeling van verswakte pasiënte en / of bejaarde pasiënte vereis mediese toesig.
FYBOGEL ORANGE moet nie saam met medisyne gebruik word wat bekend is dat dit peristaltiese beweging inhibeer nie (bv. Opioïede)
Aanhoudende hardlywigheid moet ondersoek word. Die aanhoudende gebruik van lakseermiddels moet vermy word.
FYBOGEL ORANJE moet met voldoende vloeistof geneem word om fekale impaksie en slukdermobstruksie te voorkom.
Rektale bloeding of versuiming om te ontlas na die gebruik van 'n lakseermiddel kan 'n ernstige toestand aandui. Staak gebruik en raadpleeg 'n dokter.

Hipersensitiwiteit
ISPAGHULA-doppe bevat sterk allergene.
Blootstelling aan hierdie allergene is moontlik deur orale toediening, kontak met die vel en, in die geval van poeierformulerings, ook deur inaseming.
As gevolg van hierdie allergiese potensiaal, kan individue wat blootgestel word aan FYBOGEL ORANGE hipersensitiwiteitsreaksies soos rinitis, konjunktivitis, brongospasma en in sommige gevalle anafilakse ontwikkel. Kutane simptome soos eksanteem en / of pruritus is ook al gerapporteer.

Swangerskap en Borsvoeding
Veiligheid en doeltreffendheid tydens swangerskap en borsvoeding is nog nie vasgestel nie
Ispaghula word nie geabsorbeer nie, en daar is nie oortuiging dat dit in borsmelk in gaan nie
Indien u FYBOGEL ORANGE neem terwyl u swanger is of u baba borsvoed, raadpleeg asseblief u dokter, apteker of ander professionele gesondheidswerker vir advies.

Bestuur en gebruik van masjinerie:
Geen voorsorgmaatreëls is nodig nie. Geen invloed op die vermoë om te bestuur en masjinerie te gebruik nie

Die gebruik van ander medisyne saam met FYBOGEL ORANGE
Lig altyd u mediese dokter in as u enige ander medisyne neem. (Dit sluit aanvullende of tradisionele medisyne in).
FYBOGEL ORANGE en ander bulkvormende lakseermiddels mag die gastro-intestinale opname van ander medisyne soos hartglikosiede, Warfarin, lithium of vitamiene (soos vitamien B12) en minerale (soos kalsium, yster of sink) vertraag of verminder. Om hierdie rede moet FYBOGEL ORANGE nie ½ tot 1 uur geneem word voor of na inname van ander medisyne nie.
Diabetiese pasiënte moet ispaghula-doppe slegs onder mediese toesig neem aangesien aanpassing van antidiabetiese behandeling nodig mag wees.
Die gebruik van ISPAGHULA-doppe saam met skildklierhormone vereis mediese toesig omdat die dosis van die skildklierhormone moontlik aangepas moet word.

4. HOE OM FYBOGEL ORANGE TE NEEM
Mondelingse toediening.
Moet nie medisyne wat aan u voorgeskryf is, deel met enige ander persoon nie.
FYBOGEL ORANGE behoort nie deur kinders onder die ouderdom van 6 geneem te word. nie
Neem altyd FYBOGEL ORANGE presies soos aangedui in hierdie pamflet of soos deur u dokter, apteker of verpleegster aangewys. Raadpleeg u dokter, apteker of verpleegster as u nie seker is nie.
Tensy u dokter anders voorskryf.
Die gewone dosis is ***Volwassenes en kinders oor 12 jaar***
Een sakkie soggens en saans in 'n vol glas water ingeroer ***Bejaardes***: Daar is geen aanduiding dat die dosis vir bejaardes aangepas moet word nie.

Kinders 6 tot 12 jaar
½ - 1 vlak 5 ml medisynemaat (gebaseer op ouderdom en grootte) geroer in 'n volle glas water wat soggens en saans geneem word
FYBOGEL ORANGE moet gedurende die dag minstens ½ tot 1 uur voor of na inname van ander medisyne geneem word, en moet nie onmiddellik geneem word voordat u gaan slaap nie.
Die produk moet in 'n glas water geroer word en so gou as moontlik daarna ingeneem word, verkieslik na etes.
Indien daar geen ontlasting na 3 dae van behandeling was nie, moet 'n dokter geraadpleeg word. Die effek begin 12 - 24 uur later.
Indien daar geen ontlasting na 3 dae van behandeling was nie, moet 'n dokter geraadpleeg word.
Wanneer u FYBOGEL ORANGE voorberei vir toediening, is dit belangrik om te verhoed dat u die poeier inasem om die risiko van sensitiwiteit vir die aktiewe bestanddeel te verminder.

Indien jy meer FYBOGEL ORANGE inneem as wat jy behoort:
In die geval van oordosering, raadpleeg u dokter of apteker.
Indien daar nie een beskikbaar is nie, kontak die naaste hospitaal of gifbeheersentrum.
Die volgende mag voorkom ongemak in die buik, winderigheid en dermobstruksie
Behandeling:
Behandeling is simptomaties en ondersteunend. Voldoende vloeistofinname moet gehandhaaf word, veral as die korrels sonder water geneem is.
In die geval van oordosering, moet konserwatiewe maatreëls getref word. Die pasiënt mag ongemak en winderigheid in die buik opmerk en daar moet aandag gegee word aan die behoud van voldoende vloeistofinname, (veral as die poeier sonder water geneem is, in teenstelling met die toedieningsinstruksies.)

5. MOONTLIKE NEWE-EFFEKTE
FYBOGEL ORANGE kan newe-effekte hê.
Mees algemeen:
Gastro-intestinale afwykings: winderigheid, buikdissensie.
Slukderm- en dermobstruksie of fekale impaksie is al gerapporteer en
Nie alle newe-effekte wat vir hierdie medisyne aangemeld word, is in hierdie pamflet ingesluit nie. Indien u algemene gesondheid vererger tydens die gebruik van hierdie medisyne, raadpleeg u dokter, apteker of ander professionele gesondheidswerker vir advies.

6. BERGINGSAANWYSINGS EN VERWYDERING VAN FYBOGEL ORANGE
Hou alle medisyne buite die bereik en sig van kinders.
Moet nie FYBOGEL ORANGE gebruik na verloop van die vervaldatum wat op die karton aangedui word nie.
Bewaar by of benede 25 °C in 'n droë plek.
Moet nie wegdoen met ongebruikte medisyne in dreine en rioolstelsels nie.

7. AANBIEDING VAN FYBOGEL ORANGE
Aangebied in kartonne wat 10 en 30 sakkies bevat. Elke sakkie bevat 4,377 g van FYBOGEL ORANGE

8. IDENTIFIKASIE VAN FYBOGEL ORANGE
Geelbruin, semi-deursigtige korrels met 'n lemoen reuk

9. REGISTRASIE NOMMER
M/11.5/1

10. NAAM, BESIGHEIDSADRES EN TELEFOONNOMMER VAN DIE HOUER VAN DIE SERTIFIKAAT VAN REGISTRASIE:
Reckitt Benckiser Pharmaceuticals (Pty) Limited
8 Jet Park Road
Elandsfontein 1601
+2711 871 1611

11. DATUM VAN PUBLIKASIE VAN HIERDIE PASIËNT INLIGTING PAMFLET
- Datum op die registrasiesertifikaat: 15 Mei 1981
- Datum van die mees onlangse hersiene professionele inligtingspamflet: 15 April 2020

PI Volg asseblief die skakel om die ooreenstemmende PI te verkry: https://cpdcentre.co.za/product-inserts/FYBOGEL-ORANGE-Powder.pdf

Part No. 3189445

CUSTOMER INFO:
Minimum Point Size = 5.00pt

RB Artwork and Print Specification

Trident Reference No:	RB475715
ZEN Ref:	**TR2204838**
Action:	**D**
Brand:	Fybogel
Category:	Fibre Regularity
Segment Group:	Orange
Segment:	Powder
Pack Size:	10 / 30Pack
Market/Country:	South Africa
Date:	06/10/21
RBH Contact:	Shivesh Patel

Artwork Type: BW Commercial

Component Code (2D if applicable):	**3189445**
2nd Component Code (if applicable):	**N/A**
Parent Technical Packaging Specification:	D0268244
Finished Goods Code:	**061094**
Supply Point:	RB Hull
3rd Party Code	N/A
Pharmacode No/NE:	00110(37)
Edgemark Position:	N/A
CAD Cam Ref:	Fyb-Lft-D0268244-130x255mm
Printer:	Medica Packaging Limited (Crewe, UK)
Substrate:	Paper White

Technical & Non Printing Items

Cutter | Cutter 2 (if applicable)

Guides | Guides 2 (if applicable)

Colours (Leaflet)

Process Black 1 LTH

BARCODE INFO

Barcode Type:	N/A
Barcode Number:	N/A
Magnification:	N/A
Truncated By:	N/A
Full Height:	N/A
Bar Height (Smallest Bar):	N/A
BWR:	N/A
Encoded Data:	N/A

HEALTH ▸ HYGIENE ▸ HOME

TRIDENT

Connaught House, Connaught Road,
Kingswood Business Park, Hull, HU7 3AP, England.
T: +44 (0) 1482 828100

Please note that any low resolution paper Canon colour copies associated with this job should be referred to for content, layout and colour separation only.

UNDER NO CIRCUMSTANCES SHOULD THIS ARTWORK BE ALTERED WITHOUT PRIOR PERMISSION FROM TRIDENT.

STUDIO USE ONLY Muthukumar Rajachithambaram **v2.0**

Sm•Art check results: G=2; O=2; R=0; - MR - 06/10/21 10:47:01

mm 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250

Production line			
Manufacturing site			
Pack Tech approver	1st	2nd	
Date			
Check Criteria	**Details & Comments**	**Checks**	
		1st	2nd
Approvals			
Market Approval			
Regulatory Approval			
3rd Party Approval			
Technical Drawing/ Cutter ref no. & PPI component code			
PPI component code number/s correct on artwork?			
PPI component code number/s in correct position on artwork?			
Correct drawing for the production line?			
Profile shape & dimensions			
Graphics layout/orientation			
Unwind diagram (PPTD1022/1-20)			
Printable areas/bleed			
Varnish free areas			
Variable coding position & dimensions			
Varnish and print requirements			
Pre-printed headers (alignment and suitability)			
Embossing, Braille & Foil Blocking			
Separations on artwork			
Alignment within cutter			
Braille structure			
Verification Code Type; Pharma Code / 2D / OCV			
Bar sequence and/or number correct on artwork			
Bar sequence and/or number in correct position on artwork?			
Size (height, width, spacing, font)			
Direction of read			
Light margins and print free areas			
Colour			
Repeat distance (reeled material)			
Cross check related docs ie BOM			
Bar code Type; EAN, ITF, Code39, etc			
Magnification / width and height			
Colour (e.g. black print on white background)			
Light margins & indicators			
Bearer bars & H gauges (if required)			
Symbol grade (Pass = A,B,C; Action = D,F)			
Bar code number (human readable)			
Bar code number (encoded & hidden data)			
Confirm bar code number from source			
Cross check related docs (JDE/PID)			
Photo-electric cell mark / edge marks			
Present & per Tech drawing?			
Correct pitch?			
Additional markings			
e-mark, recycle logo etc			
Legend box (RB specification)			
Correct component code			
Correct D spec / has cutter changed?			
Correct printer / has printer changed?			
Correct Substrate			
A/W is set up appropriately for this substrate			
Edge mark details			
Pharmacode details			
Colours & print process			
Varnish			
Barcode information			
General details are correct			
Pass / Fail comments and Signature			
By approving the artwork referenced within this form I authorise it for release to the print supplier			
Additional Comments			

Version 004 07/01/2020

RB Artwork and Print Specification

Trident Reference No:	RB475715
ZEN Ref:	**TR2204838**
Action:	**D**
Brand:	Fybogel
Category:	Fibre Regularity
Segment Group:	Orange
Segment:	Powder
Pack Size:	10 / 30Pack
Market/Country:	South Africa
Date:	06/10/21
RBH Contact:	Shivesh Patel

Artwork Type: BW Commercial

Component Code (2D if applicable):	**3189445**
2nd Component Code (if applicable):	**N/A**
Parent Technical Packaging Specification:	D0268244
Finished Goods Code:	**061094**
Supply Point:	RB Hull
3rd Party Code	N/A
Pharmacode No/NE:	00110(37)
Edgemark Position:	N/A
CAD Cam Ref:	Fyb-Lft-D0268244-130x255mm
Printer:	Medica Packaging Limited (Crewe, UK)
Substrate:	Paper White

Technical & Non Printing Items

- Cutter
- Cutter 2 (if applicable)
- Guides
- Guides 2 (if applicable)

Colours (Leaflet)

Process Black	
	1
	LTH

BARCODE INFO

Barcode Type:	N/A
Barcode Number:	N/A
Magnification:	N/A
Truncated By:	N/A
Full Height:	N/A
Bar Height (Smallest Bar):	N/A
BWR:	N/A
Encoded Data:	N/A

HEALTH ▸ HYGIENE ▸ HOME

TRIDENT
Connaught House, Connaught Road,
Kingswood Business Park, Hull, HU7 3AP, England.
T: +44 (0) 1482 828100

Please note that any low resolution paper Canon colour copies associated with this job should be referred to for content, layout and colour separation only.

UNDER NO CIRCUMSTANCES SHOULD THIS ARTWORK BE ALTERED WITHOUT PRIOR PERMISSION FROM TRIDENT.

STUDIO USE ONLY Muthukumar Rajachithambaram **v2.0**

Sm•Art check results: G=2; O=2; R=0; - MR - 06/10/21 10:47:01

